Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 786 in healthy subjects and subjects with obesity
NCT05406115Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 786 in obesity (3 arms), sponsored by Amgen. Primary endpoint: Treatment-emergent Adverse Event at 40 days. Started Jul 2022; status: completed.
02
Drugs
AMG 786
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05406115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406115.